ORCID as entered in ROS

Select Publications
2016, 'Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): a phase II trial in men with castration resistant prostate cancer (mCRPC).', IL, Chicago, Vol. 34, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.e16502
,2016, 'Immune-Related Adverse Events (irAEs) Following CTLA-4 and PD-1/PD-L1 Blockade in Advanced Melanoma: A Comprehensive Rapid Autopsy Study', WA, Seattle, Vol. 96, pp. 4A - 4A, presented at 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), WA, Seattle, 12 March 2016 - 18 March 2016
,2016, 'Our Rapid Research Autopsy Program: A Solid Platform for Next Generation Clinical Trials', WA, Seattle, Vol. 96, pp. 4A - 4A, presented at 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), WA, Seattle, 12 March 2016 - 18 March 2016
,2016, 'Our Rapid Research Autopsy Program: A Solid Platform for Next Generation Clinical Trials', WA, Seattle, Vol. 29, pp. 4A - 4A, presented at 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), WA, Seattle, 12 March 2016 - 18 March 2016
,2016, 'Unique Insights into Cardiac Metastases and Tumor Biology from a Cancer Center's Rapid Research Autopsy Program', WA, Seattle, Vol. 29, pp. 81A - 81A, presented at 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), WA, Seattle, 12 March 2016 - 18 March 2016
,2016, 'Unique Insights into Cardiac Metastases and Tumor Biology from a Cancer Center's Rapid Research Autopsy Program', WA, Seattle, Vol. 96, pp. 81A - 81A, presented at 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), WA, Seattle, 12 March 2016 - 18 March 2016
,2016, 'Immune-Related Adverse Events (irAEs) Following CTLA-4 and PD-1/PD-L1 Blockade in Advanced Melanoma: A Comprehensive Rapid Autopsy Study', WA, Seattle, Vol. 29, pp. 4A - 4A, presented at 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, WA, Seattle, 12 March 2016 - 18 March 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000370302500004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2016, 'What is the role of comorbidity, frailty, and functional status in the decision-making process for older adults with cancer and their family members, oncologists, and family physician?', CA, San Francisco, Vol. 34, presented at Cancer Survivorship Symposium on Advancing Care and Research, CA, San Francisco, 15 January 2016 - 16 January 2016, http://dx.doi.org/10.1200/jco.2016.34.3_suppl.92
,2016, 'Correlation of a novel whole blood RT-PCR assay measuring AR-V7 expression with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI).', CA, San Francisco, Vol. 34, presented at American-Society-of-Clinical-Oncology Genitourinary Cancers Symposium (ASCO-GU), CA, San Francisco, 07 January 2016 - 09 January 2016, http://dx.doi.org/10.1200/jco.2016.34.2_suppl.223
,2016, 'The utility of serum CA9 in prognostication in prostate cancer', CA, San Francisco, Vol. 34, presented at Genitourinary Cancers Symposium, CA, San Francisco, 07 January 2016 - 09 January 2016, http://dx.doi.org/10.1200/jco.2016.34.2_suppl.309
,2015, 'A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.', IL, Chicago, Vol. 33, presented at 51st Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps5072
,2015, 'A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma.', IL, Chicago, Vol. 33, presented at 51st Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015
,2015, 'Brain radiosurgery and ipilimumab (Ipi) in melanoma brain metastases (MBM) patients: Does an enhanced immune response induce radionecrosis (RN)?', IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015
,2015, 'Does frailty affect response to chemotherapy in older men with metastatic castration-resistant prostate cancer?', IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358036904159&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2015, 'Molecular profiling and targeted therapy in advanced endometrial cancer.', IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5589
,2015, 'Patterns of response to anti-PD1 treatment: Comparison of three radiological response criteria and effect on overall survival (OS) in metastatic melanoma patients (MM)', IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015
,2015, 'Project Data Sphere: A first look at prostate cancer including concomitant medication use, prognosis, and toxicity.', IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5022
,2015, 'A pilot study of adoptive cell therapy with in vitro educated MART1 T cells in combination with ipilimumab for the treatment of metastatic melanoma', PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-CT226
,2015, 'Effect of pantoprazole to enhance activity of docetaxel against human tumor xenografts by inhibiting autophagy', PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-395
,2015, 'Exome analysis of an exceptional responder uncovers an activating GNAS mutation that may confer sensitivity to cytotoxic chemotherapy', PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-3898
,2015, 'Using functional and chemical genomics to identify mechanisms of Enzalutamide resistance in prostate cancer', PA, Philadelphia, Vol. 75, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-732
,2015, 'Project data sphere (PDS) in prostate cancer: A first look including concomitant medication use.', FL, Orlando, Vol. 33, presented at Genitourinary Cancers Symposium, FL, Orlando, 26 February 2015 - 28 February 2015, http://dx.doi.org/10.1200/jco.2015.33.7_suppl.204
,2011, 'Evaluation of PTEN and TMPRSS2-ERG abnormalities in prostate cancer by FISH and immunohistochemistry to address intra- and intertissue heterogeneity and disease progression.', Vol. 29, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.4651
,2011, 'Preoperative sorafenib (Sor) and cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC)', Vol. 29, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.4668
,2011, 'Use of serum and tissue biomarker analysis embedded in a phase II clinical trial of cytarabine in castration-refractory prostate cancer to investigate prostate cancer biology.', Vol. 29, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.e15022
,2011, 'Evaluation of PTEN and TMPRSS2-ERG abnormalities in prostate cancer by FISH and immunohistochemistry to address intra- and inter-tissue heterogeneity and disease progression', Vol. 71, http://dx.doi.org/10.1158/1538-7445.AM2011-5074
,2011, 'Use of serum and tissue biomarker analysis embedded in a phase II clinical trial of cytarabine in castration-refractory prostate cancer to investigate prostate cancer biology', Vol. 71, http://dx.doi.org/10.1158/1538-7445.AM2011-290
,2011, 'Use of serum and tissue biomarker analysis embedded in a phase II clinical trial of cytarabine in castration-refractory prostate cancer to investigate prostate cancer biology', Vol. 29, http://dx.doi.org/10.1200/jco.2011.29.7_suppl.59
,2011, 'Evaluation of PTEN and TMPRSS2-ERG Abnormalities in Prostate Cancer by FISH and Immunohistochemistry To Address Intra- and Inter-Tissue Heterogeneity and Disease Progression', TX, San Antonio, Vol. 24, pp. 393A - 393A, presented at 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology, TX, San Antonio, 26 February 2011 - 04 March 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287282302118&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2010, 'Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX327 study.', Vol. 28, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.4686
,2010, 'Immunohistochemical Expression of Secretory Clusterin (sCLU) in Benign and Malignant Prostate in the Context of Hormonal Therapy', DC, Washington, Vol. 23, pp. 190A - 190A, presented at 99th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), DC, Washington, 20 March 2010 - 26 March 2010
,2010, 'Immunohistochemical Expression of Secretory Clusterin (sCLU) in Benign and Malignant Prostate in the Context of Hormonal Therapy', DC, Washington, Vol. 90, pp. 190A - 190A, presented at 99th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), DC, Washington, 20 March 2010 - 26 March 2010
,2009, 'Correlations between telomere dysfunction and genomic instability in prostatic carcinogenesis', Vol. 69, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209701804103&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2008, 'Rationale and evidence for the use of sunitnib to treat patients with malignant paraganglioma/pheochromocytoma (MPP)', Vol. 26, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.14681
,2007, 'Telomere length analysis of high-grade prostatic intraepithelial neoplasia (HPIN) and adjacent stroma predicts outcome in prostate cancer and provides evidence of field carcinogenesis', CA, San Diego, Vol. 20, pp. 154A - 154A, presented at 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, CA, San Diego, 24 March 2007 - 30 March 2007, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000244922401120&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2006, 'Detection of novel variant TMPRSS2/ERG fusion transcripts suggests independent genomic alterations may underlie origin of multi-centric prostate cancer.', GA, Atlanta, Vol. 24, pp. 548S - 548S, presented at 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, GA, Atlanta, 02 June 2006 - 06 June 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000239009403484&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2006, 'Telomere dysfunction in prostatic carcinogenesis.', GA, Atlanta, Vol. 24, pp. 546S - 546S, presented at 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, GA, Atlanta, 02 June 2006 - 06 June 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000239009403477&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2006, 'Developing techniques in high-throughput telomere analysis for the study of prostatic carcinogenesis', GA, Atlanta, Vol. 19, pp. 329A - 330A, presented at 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, GA, Atlanta, 11 February 2006 - 17 February 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000234094502480&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2006, 'Developing techniques in high-throughput telomere analysis for the study of prostatic carcinogenesis', GA, Atlanta, Vol. 86, pp. 329A - 330A, presented at 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, GA, Atlanta, 11 February 2006 - 17 February 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000234207602385&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2005, 'Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC).', FL, Orlando, Vol. 23, pp. 431S - 431S, presented at 41st Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 13 May 2005 - 17 May 2005, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000230326602542&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2015, 'A randomized, open-label, phase 2 study of enzalutamide as neoadjuvant therapy for patients undergoing prostatectomy for localized prostate cancer', presented at European Cancer Congress / 18th Meeting of the European-Cancer-Organization (ECCO) / 40th Meeting of the European-Society-for-Medical-Oncology (ESMO), AUSTRIA, Vienna, 25 September 2015 - 29 September 2015, http://dx.doi.org/10.1016/S0959-8049(16)31323-5
,2015, 'Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.', presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015
,2024, 'Predicting immunotherapy toxicity through single-cell sequencing of peripheral immune cells: A pilot study.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 42, pp. e14538 - e14538, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e14538
,2024, 'Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in advanced esophagogastric cancers in a phase 1/2 trial.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 42, pp. 374 - 374, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2024 - 04 June 2024, http://dx.doi.org/10.1200/JCO.2024.42.3_suppl.374
,2024, 'A phase 2 safety and efficacy study of neoadjuvant/adjuvant darovasertib for localized ocular melanoma', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 42, presented at Special Clinical Science Symposia, ELECTR NETWORK, 29 May 2024 - 29 May 2024
,2024, 'Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)', in Journal of Clinical Oncology, American Society of Clinical Oncology, Vol. 42, presented at 2024 ASCO Annual Meeting, 29 May 2024 - 29 May 2024, http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.5055
,2024, 'Predicting immunotherapy toxicity through single-cell sequencing of peripheral immune cells: A pilot study', in Journal of Clinical Oncology, American Society of Clinical Oncology, Vol. 42, presented at 2024 ASCO Annual Meeting I, 29 May 2024 - 29 May 2024, http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.e14538
,2024, 'A meta-analysis of overall survival and response in metastatic adrenocortical carcinoma: A review of 23 prospective trials of 880 patients.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, Vol. 42, pp. 4 - 4, presented at American-Society-of-Clinical-Oncology: Genitourinary Cancers Symposium (ASCO GU), CA, San Francisco, 25 January 2024 - 27 January 2024, http://dx.doi.org/10.1200/JCO.2024.42.4_suppl.4
,2024, 'PETRANHA: Phase 1/2 study of AZD5305+novel hormonal agents in patients with metastatic prostate cancer-Interim safety and pharmacokinetic results.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, Vol. 42, pp. 123 - 123, presented at American-Society-of-Clinical-Oncology: Genitourinary Cancers Symposium (ASCO GU), CA, San Francisco, 25 January 2024 - 27 January 2024, http://dx.doi.org/10.1200/JCO.2024.42.4_suppl.123
,2024, '1607P Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)', in Annals of Oncology, Elsevier BV, Vol. 35, pp. S969 - S970, http://dx.doi.org/10.1016/j.annonc.2024.08.1688
,